The seventh batch of national optical competition patterns sort out: nearly 300 companies 61 varieties competition, Omepazole injection "26+1" competes on the same stage!

Turning out! The seventh batch of official documents of the seventh batch of National Cai finally issued. Recruitment policy documents, procurement varieties and procurement volume, application qualifications, bid opening time, place, specific bidding rules and other information.

According to the reporting catalog, a total of 61 varieties and 125 specifications are involved in this time. According to statistics, nearly 300 companies have met the application conditions. Among them, domestic companies Qilu meet the most qualified varieties and the most foreign companies Pfizer; in terms of specifically, the market competition of Omeprazole injection will be unprecedented. price competition.

It is worth noting that this collection has also increased the alternative system in terms of rules, which has a certain impact on corporate evaluation, quotation expectations, and regional selection.

In addition, in accordance with the document requirements, the enterprise that meets the application requirements must submit the application materials at the prescribed time. If it is not submitted, it will affect the centralized procurement activities of the drugs involved in the company across the country.

At 11 am on July 12, 2022, as in previous years, as in previous years, the first floor of the Dongfangmei Valley Forum Hotel Conference Center, No. 399 Lakeside Road, Fengxian District, Shanghai, the declaration information will be officially released. A new round of nearly 100 billion -level markets will be Reshuffle.

01

More varieties of more enterprises bidding

Squeeze out prices virtual high space

This new round of national collection has also been adjusted to a certain amount of rules. According to the document, in the process of bidding, the selection enterprise needs to meet the two sets of conditions at the same time:

Situation 1: The price meets one of the following clauses

1. "Unit comparable" ≤ the lowest "comparable unit price" of the same variety 1.8 times.

2. "Comparison price" ≤0.1000 yuan.

3. The "unit declaration price" decreases ≥50.00%(the decline is calculated based on the maximum valid declaration price of the corresponding specifications of the "Procurement Variety Catalog", with a percentage of the percentage, and 2 digits after the four houses and five percentage points).

Situation 2: Satisfied with the shortlisted enterprise of the situation, it meets one of the following clauses

4. After satisfying the situation, the highest level in the same variety.

5. After the situation is met, the same variety is the highest level, and calculates the ratio of the "comparable price of the highest order '/the minimum of the same breed'/the minimum of the same variety, As a result, the top 6 of China and Africa were arranged. If the ratio is equal to the 6th place, it is tied for 6th place.

It is not difficult to see from the above rules. The three conditions of "situation one" are actually classic requirements for previous collection. For this episode, if you need to confirm the selection, you need The unit comparable price '/minimum of the same variety' unit comparable price 'calculation is calculated, which means that the more shortlisted companies, the more fierce competition for the bidding companies of varieties.

At the same time, in order to further strengthen the guarantee of drug supply, the policy requirements of "main supply areas" and "preparation areas" are also very eye -catching:

1. Mainly confirm the area. The proposed enterprises are first carried out to confirm the procedures for the main region. First -ranking enterprises prefer to choose one area in the supply area. After the choice of priority, starting from the first company, all the proposed companies to be selected to confirm the remaining areas in order in order. Each of the selected enterprises to select one area at a time, repeat the above process until all areas are selected to be confirmed.

2. Prepare regions to confirm. After the main region of the main supply area is confirmed, the proposed enterprise will conduct a confirmation procedure for the preparation area. The region of each selected enterprise must be different from its main region. If the number of enterprises is selected is one, there is no need to participate in the preparation area to confirm.

According to the number of companies in the proposed selection, the number of rounds is determined, and in order to ensure the smooth selection of the preparation area, set the "selection unit". If the number of enterprises in the proposed selection is N (N≥2), each "selection unit" is from the N-1 round of the N-1 round. composition.

According to the requirements, the proposed enterprise should be confirmed in accordance with the company's production capacity to confirm the supply area. When it is the turn, it must be confirmed when the regional confirmation rules are met. Confirm the supply area in order. After the supply area is confirmed, the joint procurement office signed a memorandum with the proposed enterprise.

Since the end of 2018, my country has carried out six batches of seven -wheeled nationwide drug concentrated procurement, and a total of 234 kinds of drugs are purchased, involving a market amount of about 30%of the purchase amount of chemical drugs and biopharmaceuticals in public medical institutions. The first six batches of drugs were reduced by 53%, which was strongly squeezed out of virtual high space.

Guotai has been carried out to the seventh batch. Whether it is a national collection or a provincial -level collection and alliance collection, the procurement of drug concentration and consolidation has become a new normal for drug procurement of public medical institutions. Judging from the timeline, the seventh batch of Guotai from the industry to see the directory to the quotation is relatively long, which also means that the seventh batch of competition is more intense.

02

Multiple billions of major varieties are shortlisted

The tide of the 100 billion market price reduction is turbulent

The large market size and sufficient competition have always been a highlight of the collection. The seventh batch of national minions are still mainly large varieties. Sanofi, Novartis, Lingbei, Wei Materials, Farsonjurbi, Merck, Abbott, Aslekang, Anstela, BMS and other companies all have varieties in this collection.

According to Mine.com data, from the sales of the seventh batch of varieties in the terminal of China's public medical institutions in 2021, the total market size of TOP10 varieties of sales exceeded 30 billion yuan, nifeden horizontal control release, and Moro Peinnan injection agents 2 superLeaded 6 billion major varieties; stone medicine group (5), Chinese medicine group (4), North China Pharmaceutical (3), Yangzi Jiang Pharmaceutical (3), Zhejiang Haizheng Pharmaceutical (3) allThe above varieties are listed.Attachment: The competition pattern of the seventh batch

- END -